Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia [Yahoo! Finance]
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Does Zai Lab's Steep 86.2% Slide Mask a Long Term Value Opportunity? [Yahoo! Finance]
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Zai Lab Announces Updates to China's National Reimbursement Drug List [Yahoo! Finance]